The  Effect of Intranasal Olopatadine Hydrochloride on Influenza A and B Symptoms In Children: A Clinical Observation and Comparative Evaluation: THE EFFECT OF INTRANASAL OLOPATADINE HYDROCHLORIDE ON INFLUENZA A AND B SYMPTOMS IN CHILDREN

Vefik ARICA; Taner Adıgüzel

doi:10.5281/zenodo.16585082

Authors

Vefik ARICA Sağlık Bilimleri Üniversitesi Prof Dr Cemil Taşcıoğlu Şehir Hastanesi SUAM
Taner Adıgüzel Yalova Üniversitesi Tıp Fakültesi

DOI:

https://doi.org/10.5281/zenodo.16585082

Keywords:

Influenza, Olopatadine Hydrochloride, nasal congestion, sneeze

Abstract

Objective:

This study aims to evaluate the effects of intranasal Olopatadine Hydrochloride on nasal and systemic symptoms in pediatric patients diagnosed with influenza A or B infection.

Materials and Methods:

Children aged 6-18 years who presented to the Pediatric Outpatient Clinics of Health Sciences University Prof. Dr. Cemil Taşcıoğlu City Hospital and Yalova Training and Research Hospital between 1 January and 15 March 2025 and were diagnosed with influenza A or B were retrospectively evaluated. Patients (n=50) who received appropriately dosed intranasal Olopatadine Hydrochloride alongside symptomatic treatment underwent face-to-face interviews regarding their previous treatment experience, including symptom profiles and duration.

Results:

In the influenza A-positive group (n=25), the duration of nasal congestion was 2 days in the group receiving intranasal Olopatadine Hydrochloride (n=13) versus 6 days in the group receiving no Olopatadine Hydrochloride (n=12). Sneezing lasted 1 day in the Olopatadine group and 7 days in the group receiving no Olopatadine. No significant differences were observed in systemic symptoms. A significant reduction in the duration of nasal congestion and sneezing was observed in the Olopatadine group (p < 0.001).

In the influenza B-positive group (n=25), nasal congestion lasted 1 day in the Olopatadine group (n=13) and 3 days in the other group (n=12). Sneezing lasted 1 day in the Olopatadine group and 4 days in the other. Again, there were no significant differences in systemic symptoms. A significant reduction in nasal congestion and sneezing duration was observed in the Olopatadine group (p<0.01).

Among the patients with concurrent influenza A and B infection (n=5), nasal congestion lasted 1 day in those treated with Olopatadine (n=3) compared to 6 days in the other group (n=2). Sneezing lasted 1 day in the Olopatadine group and 5 days in the other. No significant difference was found in systemic symptoms. However, there was a significant reduction in nasal congestion and sneezing duration in the Olopatadine group (p<0.001).

Conclusion: Intranasal Olopatadine may significantly reduce nasal symptoms in children with influenza A and B infections.

Downloads

Download data is not yet available.

References

REFERENCES

Eccles R. Understanding the symptoms of the common cold and influenza. Lancet Infect Dis. 2005;5(11):718–725.

Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol. 2001;108(1 Suppl):S2–S8.

Dykewicz MS, Wallace DV, et al. Treatment of seasonal allergic rhinitis: An evidence-based focused 2017 guideline update. Ann Allergy Asthma Immunol. 2017;119(6):489–511.

Kawauchi H, et al. Effects of intranasal antihistamines in allergic rhinitis. Allergol Int. 2009;58(2):157–165.

Mark B. Abelson, MD, Lawrence Spitalny, MD: Combined analysis of two studies using the conjunctival allergen challenge model to evaluate Olopatadine Hydrochloride, a new ophthalmic antiallergic agent with dual activity. Am J Ophthalmol 125:797-804, 1998.

Ohmori K, Ikemura T, Kobayashi H, Mukouyama A: Pharmacological, pharmacokinetic and clinical properties of Olopatadine Hydrochloride' (Olopatadine), an antiallergic drug, Nippon Yakurigaku Zasshi 118(1):51-8, 2001.

Nakano K, Takamatsu S. [Histamine produced by macrophage and T lymphocyte: a new type of signal transducer]. Nihon yakurigaku zasshi Folia pharmacologica Japonica 2001;118(1):15-22.

Shiraishi M, Hirasawa N, Oikawa S, Kobayashi Y, Ohuchi K. Analysis of histamine-producing cells at the late phase of allergic inflammation in rats. Immunol 2000;99(4):600-6.

Ikemura T, Manabe H, Sasaki Y, Ishii H, Onuma K, Miki I, et al. KW-4679, an antiallergic drug, inhibits the production of inflammatory lipids in human polymorphonuclear leukocytes and guinea pig eosinophils. Int Arch Allergy Immunol 1996;110(1):57-63.

Nonaka H. Effect of KW-4679, a novel antiallergic agent, on histamine H1 receptor. Jpn J Pharmacol 1993;61(1):87.

Sasaki Y IY, Ikemura T, Okamura K, Miyake K, Ishii H, et al. Effect of KW-4679, an novel antiallergic drug, on histamine and leukotriene release from rat perito neal exudates cells. Clin Pharmacol Ther 1995;5(1):1837-49.

Sharif NA, Xu SX, Yanni JM. Olopatadine (AL-4943A): ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis. J Ocul Pharmacol Ther 1996;12(4):401-7.

Sur DK, Scandale S. Treatment of allergic rhinitis. Am Fam Physician 2010;81:1440-6.

ClinicalTrials.gov. Olopatadine Nasal Spray in the Treatment of Upper Respiratory Tract Symptoms. NCTXXXXXXX

Blaiss MS. Important aspects in the management of allergic rhinitis: compliance, cost, and quality of life. Allergy Asthma Proc. 2007;28(3):249–254.

The Effect of Intranasal Olopatadine Hydrochloride on Influenza A and B Symptoms In Children: A Clinical Observation and Comparative Evaluation